Tissue inadequacy and operational challenges may limit lung cancer comprehensive biomarker testing. Here, we describe the initial implementation of a tailored tissue molecular journey at Oncoclínicas ...
Comprehensive biomarker testing is central to the management of metastatic non-small cell lung cancer (NSCLC). Widespread ...
A new AI tool reads lung cancer biopsy slides in under an hour, accurately predicting mutations and saving patients delays, costs and tissue loss, marking a turning point in precision cancer care.
NORTHFIELD, Ill.--(BUSINESS WIRE)--The College of American Pathologists (CAP) in collaboration with the International Association for the Study of Lung Cancer (IASLC), Pulmonary Pathology Society (PPS ...
IRVING, Texas, May 12, 2025 /PRNewswire/ -- Caris Life Sciences®(Caris), a leading next-generation AI TechBio company and precision medicine pioneer, performs MET Immunohistochemistry (IHC) testing as ...
Hengrui's Camrelizumab Combo Therapy Doubles the Five -Year Survival of Patients with Advanced Squamous Lung Cancer - A Potential Paradigm Shift in Clinical Outcome for this Difficult-to Treat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback